Compare TSN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSN | RPRX |
|---|---|---|
| Founded | 1935 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 19.5B |
| IPO Year | 1994 | 2020 |
| Metric | TSN | RPRX |
|---|---|---|
| Price | $64.20 | $48.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $66.90 | $50.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.11% | 1.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.24 | ★ 1.78 |
| Revenue | ★ $54,441,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $5.63 | $38.30 |
| Revenue Next Year | $1.13 | $4.80 |
| P/E Ratio | $272.88 | ★ $26.88 |
| Revenue Growth | 2.12 | ★ 5.06 |
| 52 Week Low | $50.56 | $31.58 |
| 52 Week High | $66.24 | $49.06 |
| Indicator | TSN | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 59.71 |
| Support Level | $61.99 | $35.32 |
| Resistance Level | $64.93 | $49.06 |
| Average True Range (ATR) | 1.23 | 0.94 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 77.89 | 73.40 |
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, composing about 40% and 30% of sales, respectively. Prepared foods constituted 18% of fiscal 2025 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.